CENTOGENE Announces the Nomination of Rene Just as Chief Financial Officer
May 26, 2021 06:30 ET
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 26, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENE Appoints Michael Motz as Chief Commercial Officer, Pharmaceuticals
May 18, 2021 06:30 ET
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 18, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world...
CENTOGENE Extends Global Parkinson’s Disease Study
May 10, 2021 06:30 ET
|
CENTOGENE GmbH
Providing patients with genetic testing designed to accelerate the diagnosis and personalized treatment of Parkinson’s disease (PD) The Rostock International Parkinson's Disease (ROPAD) Study aims to...
New CentoMD® 6.0 Update Brings Deeper Insights Into Rare Diseases
May 06, 2021 06:30 ET
|
CENTOGENE GmbH
Database has grown to more than 465,000 analyzed patients, with more than 225,000 being linked to HPO termsRelease includes increase of almost 19 million to over 31 million unique variants New...
CENTOGENE Discovers Six New Rare Diseases by Leveraging the Strength of Its Bio/Databank
May 05, 2021 06:30 ET
|
CENTOGENE GmbH
More than half of patients with genetic diseases remain undiagnosed, even after performing Exome and Genome SequencingBy performing deep genetic analyses and Bio/Databank mining, CENTOGENE discovers...
CENTOGENE Reports Record Fourth Quarter and Full Year 2020 Financial Results
April 15, 2021 06:30 ET
|
CENTOGENE GmbH
Revenues more than doubled in FY 2020 compared to FY 2019 to a record €128.4 million, with Q4 2020 revenues nearly quadrupling year-over-year to a record €70.3 millionAchieved highest annual adjusted...
CENTOGENE Announces Voting Results of Extraordinary General Meeting
December 18, 2020 10:02 ET
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare diseases...
CENTOGENE Reports Third-Quarter 2020 Financial Results and Increases Full Year Guidance
December 16, 2020 06:30 ET
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare diseases...
CENTOGENE to Report Third-Quarter 2020 Financial Results on December 16, 2020
December 09, 2020 06:30 ET
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world...
CENTOGENE and Alnylam Pharmaceuticals Launch a New Clinical Program Aimed at Revolutionizing the Diagnosis of Hereditary Transthyretin-Related Amyloidosis (“ATTRv”)
December 08, 2020 06:30 ET
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN and MUNICH, Germany, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that...